Osteogenesis imperfecta (OI) Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

United Kingdom

High-Risk Population

People with a pathogenic variant associated with OI are at risk of the disorder; it may be inherited from an affected parent or arise through a new genetic variant. Within the affected population, people with severe skeletal fragility, frequent fractures, progressive deformity or vertebral involvement require particular attention.

Key Diagnostic Method

Diagnosis combines clinical assessment, skeletal imaging and molecular genetic testing. A history of recurrent low-trauma fractures, characteristic bone deformities, short stature, blue sclerae or dentinogenesis imperfecta may prompt investigation.

Major Risk Factor

The principal underlying risk factor is a disease-causing genetic variant. Inherited and de novo variants can both cause OI, and the inheritance pattern depends on the specific gene and variant. For fracture burden, clinically important factors include disease severity, previous fractures, bone deformity and reduced bone strength.

Major gap in the market

A major gap is the lack of harmonized national data on diagnosed OI cases, fracture burden, treatment access and long-term outcomes across the eight countries. A 2023 European review found that registry practices and data elements varied, supporting the need for common, high-quality data systems.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

On a macro level, the global population prevalence typically ranges between 2.35 and 4.7 cases per 100,000 individuals. Real-world European Delphi tracking indicates that the diagnosed prevalence changes across a patient's lifespan due to transition gaps in healthcare systems. For example, data maps a pediatric prevalence of 0.88 per 10,000 children, which drops to an adult prevalence of 0.50 per 10,000 individuals as mild adult cases frequently drift away from active clinical tracking.

Gender-Specific Cases of the Disease

Epidemiological data confirms that males and females inherit, manifest, and are diagnosed with the condition at a true 1:1 equal ratio globally. Large genetic epidemiology studies (such as those tracking European cohorts) have observed a unique gender skew regarding dental health. In patients with Type I OI (the mildest and largest patient pool), DI (brittle, discolored teeth) is significantly more prevalent in females than in males (affecting roughly 22% of females vs. 9% of males).

Age-Specific Cases of the Disease

Epidemiological data highlights a sharp decline in physical health-related quality of life (HR-QOL) in later years due to cumulative damage. Chronic pain (affecting 41.8% of adults), early-onset osteoarthritis from joint hypermobility, and restrictive pulmonary disease from childhood scoliosis culminate to reduce overall adult life expectancy.

Ethnicity-Wise Cases of the Disease

From a baseline genetic standpoint, Osteogenesis Imperfecta (OI) affects all racial and ethnic groups with equal biological frequency. Because 85% to 90% of cases are caused by spontaneous or inherited autosomal dominant mutations in the COL1A1 and COL1A2 genes, the condition lacks a primary ethnic or racial bias.

Mortality and Survival Analysis of the Disease

Comprehensive longitudinal cohort data published in the Journal of Bone and Mineral Research indicates that individuals with OI experience an all-cause mortality hazard ratio (HR) of 2.90. The median survival times reflect a notable reduction in lifespan, for males with OI: Median survival is 72.4 years, compared to 81.9 years in the reference population (a 9.5-year reduction) and for females with OI: Median survival is 77.4 years, compared to 84.5 years in the reference population (a 7.1-year reduction).

Disease Type

Prevalence

Type I

Most common form (50-60% of cases). Quantitative defect (underproduction of structurally normal collagen). Near-normal stature, low bone deformity, fractures typically peak before puberty. High rates of adult hearing loss (~50%).

Type II

Most severe form. Severe qualitative structural collagen defect. Marked by extreme bone fragility with multiple fractures occurring in utero or at birth, an abnormally small rib cage, and severe lung hypoplasia leading to death shortly after birth.

Type III

Most severe non-lethal form. Severe structural collagen deformation. Characterized by progressive limb bowing, very short stature, barrel chest, severe kyphoscoliosis, and multiple fractures present at birth. Most individuals require wheelchair assistance.

Type IV

A moderate clinical midpoint between Types I and III. Mild-to-moderate bone deformity, short stature, and frequent long-bone and vertebral compression fractures. Sclera color transitions to normal after infancy.

Country

Key Insights

United States

In the United States, the diagnosed prevalent population of Osteogenesis Imperfecta (OI) stands at approximately 40,000 cases, representing roughly 55% of all documented cases across the world's major pharmaceutical forecasting markets. Broad historical estimates mapping overall population parameters place the cumulative patient pool between 25,000 and 50,000 affected individuals.

Germany

In Germany, Osteogenesis Imperfecta (OI) represents a significant clinical cohort within the rare disease landscape. Centralized multi-market epidemiological analyses reveal that Germany holds the highest prevalence of OI among the major European nations. Germany accounts for the largest distinct slice at 25% to 26% of all European cases. France follows as the runner-up at roughly 20%. Germany's baseline population prevalence ranges between 0.50 and 0.80 per 10,000 inhabitants (or roughly 1 in 13,000 to 17,000 individuals).

France

In France, the epidemiological landscape of Osteogenesis Imperfecta (OI) is characterized by highly structured public registries and a well-coordinated national network for rare diseases. Epidemiological modeling tracks the total living pool of affected individuals in France at approximately 3,000 to 6,000 individuals.

Italy

Mirroring macro-European epidemiological data, Italy’s baseline population point prevalence matches the broader continental range of 0.50 to 0.70 per 10,000 inhabitants (or roughly 1 in 14,000 to 20,000 individuals). Italy comprises an estimated portion of the European pool, translated to approximately 3,500 to 4,500 diagnosed living individuals nationwide.

Spain

In Spain, the diagnosed prevalent population of Osteogenesis Imperfecta (OI) is estimated at 0.56 per 10,000 inhabitants, representing a total of 2,669 managed patients nationwide. Comprises 715 pediatric patients (prevalence rate of 0.88 per 10,000 children) and 1,954 adult patients (prevalence rate of 0.50 per 10,000 adults).

United Kingdom

In the United Kingdom, the epidemiology of Osteogenesis Imperfecta (OI) is robustly documented, primarily anchored by data from the National Health Service (NHS) and the Brittle Bone Society (BBS): the world's first registered OI charity. There are approximately 5,000 individuals actively living with diagnosed Osteogenesis Imperfecta across the United Kingdom.

Japan

Japan accounts for approximately 10% of the total 8MM prevalent cases. This positions Japan’s total diagnosed prevalent patient pool at approximately 7,200 individuals. In alignment with global baselines, the standard birth incidence in Japan stays uniform at 1 in 15,000 to 20,000 live births.

India

Public health data tracks the incidence of OI in India at approximately 1 in 15,000 to 1 in 20,000 live births. Because India lacks a single, mandatory rare-disease registry covering its entire population, calculations rely on macro epidemiological models. Given India’s vast population, the estimated living, diagnosed prevalent pool ranges between 70,000 and 95,000 individuals.